Ivosidenib in Participants With Locally Advanced or Metastatic Conventional Chondrosarcoma Untreated or Previously Treated With 1 Systemic Treatment Regimen

Conditions: Locally Advanced or Metastatic Conventional Chondrosarcoma With an IDH1 Mutation, Untreated or Previously Treated With 1 Systemic Treatment Regimen Interventions: Drug: Ivosidenib 500mg; Drug: Placebo Sponsors: Servier Bio-Innovation LLC; Institut de Recherches Internationales Servier Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials